Paper Details

  1. Home
  2. Paper Details

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.

Author: , AbelsonMark B, GomesPaul J, GowJames A, McNamaraTimothy R, TorkildsenGail L, WilliamsJon I

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Bepotastine besilate, a selective histamine H(1)-receptor antagonist, is being investigated as a potential ophthalmic medication for allergic conjunctivitis based on its effectiveness and tolerability in treating allergic symptoms.
Paper Details　
Original Abstract of the Article :
Bepotastine besilate is a highly selective histamine H(1)-receptor antagonist with antihistaminic, mast cell stabilizing, and anti-inflammatory activity. Based on a history of clinical effectiveness and tolerability of oral bepotastine besilate in the treatment of allergic symptoms, bepotastine besi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2009.09.001

データ提供：米国国立医学図書館（NLM）

Bepotastine Besilate: A New Oasis for Allergic Conjunctivitis

The field of ophthalmology is constantly searching for new and effective treatments for eye conditions. This study investigates the efficacy and speed of action of bepotastine besilate, an antihistamine, in treating allergic conjunctivitis. It's like a skilled ophthalmologist searching for a quick and effective remedy for itchy, watery eyes.

Rapid Relief: A Beacon in the Desert

The study demonstrates that bepotastine besilate offers rapid relief from the symptoms of allergic conjunctivitis, providing a much-needed respite from the discomfort. It's like finding a cool spring in a hot desert, offering immediate relief from the burning sensation. The study also highlights the drug's safety and tolerability in adults and children, making it a potentially valuable treatment option for a wide range of patients. It's a reminder that even in the most sensitive areas of the body, there can be effective solutions to alleviate discomfort.

Conquering Allergies: A Journey of Discovery

This research provides a promising new avenue for treating allergic conjunctivitis. It's a reminder that our understanding of allergies is constantly evolving, and new treatments are emerging to combat the discomfort they cause. This study encourages further research to explore the full potential of bepotastine besilate and develop even more effective solutions for treating allergies. Just like a skilled navigator charting a new course through the desert, we must continue to explore new pathways to alleviate suffering and promote health.

Dr.Camel's Conclusion

The study showcases bepotastine besilate as a potential game-changer in the treatment of allergic conjunctivitis. It's like finding a new source of fresh water in a parched desert, offering relief and hope for those suffering from itchy, watery eyes. This research encourages us to continue exploring new and innovative treatments for allergies, striving for a world where everyone can enjoy clear and comfortable vision.

Date :
  1. Date Completed 2010-01-18
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

19843481

DOI: Digital Object Identifier

10.1016/j.clinthera.2009.09.001

Related Literature

Article Analysis
・Effects of bepotastine ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.